Overexpressed C-C motif chemokine receptor 2 (CCR2) promotes the progression of early-stage BC via stromal-dependent C-C motif chemokine ligand 2 (CCL2) expression, therefore, chemokine signaling can affect the therapy and outcomes of BC patients (Brummer et al., 2018). This evidence concerns the gene CCL2 and breast cancer.